138 related articles for article (PubMed ID: 24824511)
1. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract][Full Text] [Related]
2. Questioning the 10-year Life Expectancy Rule for High-grade Prostate Cancer: Comparative Effectiveness of Aggressive vs Nonaggressive Treatment of High-grade Disease in Older Men With Differing Comorbid Disease Burdens.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Urology; 2016 Jul; 93():68-76. PubMed ID: 27079130
[TBL] [Abstract][Full Text] [Related]
3. Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Dash A; Greenfield S; Litwin MS
Cancer; 2013 Oct; 119(19):3446-53. PubMed ID: 23861016
[TBL] [Abstract][Full Text] [Related]
4. Weighted versus unweighted Charlson score to predict long-term other-cause mortality in men with early-stage prostate cancer.
Daskivich TJ; Kwan L; Dash A; Greenfield S; Litwin MS
Eur Urol; 2014 Dec; 66(6):1002-9. PubMed ID: 24924554
[TBL] [Abstract][Full Text] [Related]
5. Overtreatment of men with low-risk prostate cancer and significant comorbidity.
Daskivich TJ; Chamie K; Kwan L; Labo J; Palvolgyi R; Dash A; Greenfield S; Litwin MS
Cancer; 2011 May; 117(10):2058-66. PubMed ID: 21523717
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: a population-based analysis.
Abdollah F; Schmitges J; Sun M; Jeldres C; Tian Z; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Int J Urol; 2012 Sep; 19(9):836-44. PubMed ID: 22574746
[TBL] [Abstract][Full Text] [Related]
7. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics.
Abdollah F; Sun M; Schmitges J; Thuret R; Bianchi M; Shariat SF; Briganti A; Jeldres C; Perrotte P; Montorsi F; Karakiewicz PI
J Urol; 2012 Jul; 188(1):73-83. PubMed ID: 22578732
[TBL] [Abstract][Full Text] [Related]
8. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
[TBL] [Abstract][Full Text] [Related]
9. An Age Adjusted Comorbidity Index to Predict Long-Term, Other Cause Mortality in Men with Prostate Cancer.
Daskivich TJ; Kwan L; Dash A; Saigal C; Litwin MS
J Urol; 2015 Jul; 194(1):73-8. PubMed ID: 25623745
[TBL] [Abstract][Full Text] [Related]
10. Impact of comorbidity on survival of Danish prostate cancer patients, 1995-2006: a population-based cohort study.
Lund L; Borre M; Jacobsen J; Sørensen HT; Nørgaard M
Urology; 2008 Dec; 72(6):1258-62. PubMed ID: 18342917
[TBL] [Abstract][Full Text] [Related]
11. Comorbidity and competing risks for mortality in men with prostate cancer.
Daskivich TJ; Chamie K; Kwan L; Labo J; Dash A; Greenfield S; Litwin MS
Cancer; 2011 Oct; 117(20):4642-50. PubMed ID: 21480201
[TBL] [Abstract][Full Text] [Related]
12. Marital status and prostate cancer outcomes.
Tyson MD; Andrews PE; Etzioni DA; Ferrigni RG; Humphreys MR; Swanson SK; Castle EK
Can J Urol; 2013 Apr; 20(2):6702-6. PubMed ID: 23587510
[TBL] [Abstract][Full Text] [Related]
13. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
[TBL] [Abstract][Full Text] [Related]
14. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
Aizer AA; Chen MH; Hattangadi J; D'Amico AV
BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
[TBL] [Abstract][Full Text] [Related]
15. Survival associated with treatment vs observation of localized prostate cancer in elderly men.
Wong YN; Mitra N; Hudes G; Localio R; Schwartz JS; Wan F; Montagnet C; Armstrong K
JAMA; 2006 Dec; 296(22):2683-93. PubMed ID: 17164454
[TBL] [Abstract][Full Text] [Related]
16. The association between insurance status and prostate cancer outcomes: implications for the Affordable Care Act.
Mahal BA; Aizer AA; Ziehr DR; Hyatt AS; Lago-Hernandez C; Chen YW; Choueiri TK; Hu JC; Sweeney CJ; Beard CJ; D'Amico AV; Martin NE; Trinh QD; Nguyen PL
Prostate Cancer Prostatic Dis; 2014 Sep; 17(3):273-9. PubMed ID: 24980272
[TBL] [Abstract][Full Text] [Related]
17. Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.
Kaplan AL; Hu JC
Urology; 2013 Aug; 82(2):321-6. PubMed ID: 23706552
[TBL] [Abstract][Full Text] [Related]
18. Interaction of adjuvant androgen deprivation therapy with patient comorbidity status on overall survival after radical prostatectomy for high-risk prostate cancer.
Linder BJ; Boorjian SA; Umbreit EC; Carlson RE; Rangel LJ; Bergstralh EJ; Karnes RJ
Int J Urol; 2013 Aug; 20(8):798-805. PubMed ID: 23278850
[TBL] [Abstract][Full Text] [Related]
19. Cancer-specific and other-cause mortality after radical prostatectomy versus observation in patients with prostate cancer: competing-risks analysis of a large North American population-based cohort.
Abdollah F; Sun M; Schmitges J; Tian Z; Jeldres C; Briganti A; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
Eur Urol; 2011 Nov; 60(5):920-30. PubMed ID: 21741762
[TBL] [Abstract][Full Text] [Related]
20. Population based study of hormonal therapy and survival in men with metastatic prostate cancer.
Lu-Yao G; Moore DF; Oleynick JU; DiPaola RS; Yao SL
J Urol; 2007 Feb; 177(2):535-9. PubMed ID: 17222628
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
